Quest Diagnostics Inc Receives a Buy from Credit Suisse


Credit Suisse analyst A.J. Rice maintained a Buy rating on Quest Diagnostics Inc (NYSE: DGX) today and set a price target of $121. The company’s shares opened today at $103.60.

According to TipRanks.com, Rice is a 4-star analyst with an average return of 9.7% and a 61.5% success rate. Rice covers the Services sector, focusing on stocks such as Encompass Health Corporation, AMN Healthcare Services Inc, and Healthcare Services.

Currently, the analyst consensus on Quest Diagnostics Inc is Strong Buy and the average price target is $114, representing a 10.0% upside.

In a report released today, Mizuho Securities also reiterated a Buy rating on the stock.

See today’s analyst top recommended stocks >>

Based on Quest Diagnostics Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.88 billion and net profit of $176 million. In comparison, last year the company earned revenue of $1.9 billion and had a net profit of $163 million.

Based on the recent corporate insider activity of 70 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Quest Diagnostics, Inc. engages in the provision fo diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts